Clinical Trial: A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07710716) titled 'A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients' on July 13.

Brief Summary: The aim of this study is to assess the clinical adoption, treatment patterns, and safety of adjuvant ribociclib use in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) patients. This is a multi-country study using secondary real-world data sources.

Study Start Date: April 09

Study Type: OBSERVATIONAL

Condition: Breast Cancer

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: Novartis Pharmaceutic...